Caspofungin Acetate is owned by Fresenius Kabi Usa.
Caspofungin Acetate contains Caspofungin Acetate.
Caspofungin Acetate has a total of 1 drug patent out of which 0 drug patents have expired.
Caspofungin Acetate was authorised for market use on 30 December, 2016.
Caspofungin Acetate is available in powder;intravenous dosage forms.
The generics of Caspofungin Acetate are possible to be released after 21 December, 2032.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9636407||FRESENIUS KABI USA||Caspofungin acetate formulations|| |
(9 years from now)
Market Authorisation Date: 30 December, 2016
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic